GridAI Technologies Corp. Announces Receipt of NASDAQ Notice Regarding Late Form 10-K Filing
Boca Raton, Florida--(Newsfile Corp. - April 28, 2026) - GridAI Technologies Corp. (NASDAQ: GRDX) (the "Company") today announced that On April 22, 2026, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with the filing of periodic financial reports requirement for continued listing on The Nasdaq Capital Market, under Listing Rule 5250(c)(1), because the Company has not yet file
2026-04-28 5:20 PM EDT | GridAI Technologies Corp.
Envoy Medical Highlights First Clinical Data Presentations from Pivotal Clinical Study of Fully Implanted Acclaim(R) Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - April 28, 2026) - Envoy Medical® Inc. (NASDA
Biotechnologies, Soins de santé et hôpitaux
2026-04-28 8:30 AM EDT | Envoy Medical, Inc.
Restart Life Sciences' Wholly Owned Subsidiary Holy Crap Foods Launches on Walmart Canada's Digital Marketplace
Vancouver, British Columbia--(Newsfile Corp. - April 28, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its wholly owned subsidiary, Holy Crap Foods Inc. ("Holy Crap Foods"), has secured a listing on Walmart Canada's online marketplace, Walmart.ca. The Company's initial product lineup has been accepted for sale, with inventory currently in transit to Walmart's fulfillment network. Product availability
Technologies, Biotechnologies, Santé
2026-04-28 8:00 AM EDT | Restart Life Sciences Corp.
MustGrow Receives Georgia Registration for TerraSante(TM) Biofertility Product
Saskatoon, Saskatchewan--(Newsfile Corp. - April 28, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGRO
Agriculture, Biotechnologies, Cannabis, Sélectionneurs de cannabis
2026-04-28 7:00 AM EDT | MustGrow Biologics Corp.
InMed Pharmaceuticals Amends Preferred Investment Options
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that it has entered into amending agreements in respect of preferred investment options previously entered into with each of Sabby Volatility Warrant Master Fund, Ltd.
Biotechnologies, Pharmaceutique
2026-04-27 5:30 PM EDT | InMed Pharmaceuticals
OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET
New York, New York--(Newsfile Corp. - April 27, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world le
2026-04-27 4:01 PM EDT | OS Therapies
Bachem Secures Financing of Strategic Growth Initiatives
Bubendorf, Switzerland--(Newsfile Corp. - April 27, 2026) - Bachem Holding AG (SIX: BANB) (“Bachem”) announced today the closing of a revolving credit facility of C
Biotechnologies, Produits chimiques, Soins de santé et hôpitaux, Pharmaceutique
2026-04-27 1:03 AM EDT | Bachem Holding AG
Defence Therapeutics Announces Grant of Restricted Stock Units
Montreal, Quebec--(Newsfile Corp. - April 24, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, wishes to announce that the board of directors of the Company approved the grant of 200,000 incentive restricted stock units ("RSUs") to Mr. Sebastien Plouffe, CEO and Director of the Company, vesting immediately. Each RSU entitles the
Biotechnologies, Pharmaceutique, Santé
2026-04-24 6:30 PM EDT | Defence Therapeutics Inc.
BYT Holdings Ltd. Announces Delay of Annual Filings and Application for a Management Cease Trade Order
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2026) - BYT Holdings Ltd. (CSE: BYT) ("BYT" or the "Company") announces that it will require additional time to identify and appoint an external auditor registered in Canada to complete the audit for the Company's financial year ended December 31, 2025, including the 2024 comparative year, in accordance with the Canadian Generally Accepted Auditing Standards ("GAAS"). As a result, the Company will not be able to file its audited annual
Technologies, Biotechnologies, Construction / bâtiments, Machinerie
2026-04-24 2:28 PM EDT | BYT Holdings Ltd.
iSpecimen Announces 1-for-40 Reverse Stock Split
Woburn, Massachusetts--(Newsfile Corp. - April 24, 2026) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it will effect a reverse stock split of its issued and outstanding shares of common stock, par value $0.0001 per share, as well as any shares of common stock held by the Company in treasury, at a rati
2026-04-24 9:00 AM EDT | iSpecimen Inc.
Sernova Biotherapeutics Announces Closing of Recently Approved Financings
Ontario and Boston, Massachusetts--(Newsfile Corp. - April 23, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSHO) (XETRA: PSHO) ("Sernova" or the "Company"), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced that it has completed the final closing of a series of previously disclosed financing transactions, following receipt of shareholder approval at the Compan
2026-04-23 4:15 PM EDT | Sernova Biotherapeutics
Restart Life Sciences' Wholly Owned Subsidiary Holy Crap Foods Reports over 500,000 Units Sold, Highlighting Strong Consumer Adoption
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its wholly owned subsidiary, Holy Crap Foods Inc. ("Holy Crap"), has surpassed 500,000 units sold from January 2023 through March 2026. This milestone reflects continued consumer adoption, repeat purchasing behavior, and steady brand development within the "better-for-you" food category. The C
Technologies, Biotechnologies, Santé
2026-04-23 8:00 AM EDT | Restart Life Sciences Corp.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - April 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will provide an overview of the Company's INTASYL siRNA platform and discuss recent clinical progress and priorities,
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-23 7:00 AM EDT | Phio Pharmaceuticals Corp.
Optimi Health Files LIFE Offering Document in Connection with NASDAQ Listing
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that further to its press release dated March 16, 2026, it intends to complete a portion of its previously announced offering of common shares (the "Offering") in Canada pursuant to the Listed Issuer Financing Exemption c
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-04-23 7:00 AM EDT | Optimi Health Corp.
Trenchant Technologies Capital Corp. Completes Unwinding of Previous Limitless Quantum Acquisition and Corporate Updates
Vancouver, British Columbia--(Newsfile Corp. - April 22, 2026) - Trenchant Technologies Capital Corp. (CSE: AITT) (OTCQB: AITTF) ("Trenchant" or the "Company") announces that it has completed the unwinding of the Company's acquisition of Limitless Quantum Computing Solutions Inc. ("Limitless Quantum") (collectively, the "Unwinding Transaction"), as previously announced on April 8, 2026. The Compan
Technologies, Services bancaires / financiers, Biotechnologies, Soins de santé et hôpitaux
2026-04-22 8:30 AM EDT | Trenchant Technologies Capital Corp.
Envoy Medical Reaches Critical Milestone in Pivotal Clinical Trial of Fully Implanted Acclaim(R) Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - April 22, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that all 56 patients implanted and enrolled in its pivotal clinical trial evaluating the fully implanted Acclaim® cochlear implant have been through their "Activation Visits," when a patient's device is initially turned on for the first time. "The conclusio
Biotechnologies, Soins de santé et hôpitaux
2026-04-22 8:00 AM EDT | Envoy Medical, Inc.
Restart Life Sciences Provides Performance and Revenue Trend Update on Newly Acquired Superseed Cereals and Oatmeal Brand Portfolio
Vancouver, British Columbia--(Newsfile Corp. - April 22, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide an operational update on its wholly owned subsidiary following the successful completion of its acquisition of Holy Crap Foods Inc. Since the closing of the transaction on February 27, 2026, Restart has been transitioning ownership and integrating portfolio operations under its leadership. The Compa
Technologies, Biotechnologies, Santé
2026-04-22 6:00 AM EDT | Restart Life Sciences Corp.
PreveCeutical Announces Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - April 22, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 40,000,000 units (each, a "Unit") in the capital of the Company at a price of $0.
Biotechnologies, Pharmaceutique, Santé
2026-04-22 3:00 AM EDT | PreveCeutical Medical Inc.
Izotropic Announces Debt Settlement
British Columbia and Sacramento, California--(Newsfile Corp. - April 21, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has entered into a debt settlement agreement (the "Agreement") with a lender (the "Le
2026-04-21 2:09 PM EDT | Izotropic Corporation
Microbiome Labs relaunches BiomeFX to advance gut microbiome interpretation
Franklinton, North Carolina--(Newsfile Corp. - April 21, 2026) - Microbiome Labs™, a leader in microbiome-based solutions, today announced the relaunch of its BiomeFX™ Functional Microbiome Analysis in partnership with Jona, the AI-powered gut microbiome company. The interpretation layer of BiomeFX is now powered by Jona AI, a clinical-grade microbiome anal
2026-04-21 9:00 AM EDT | Microbiome Labs